Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Cardiovascular Diseases (CVs) are one of the main causes of mortality and disability around the world. Advances in drug treatment have greatly improved survival and quality of life in the past decades, but associated adverse events remain a relevant problem. Pharmacogenetics can help individualize c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xandra García-González, Sara Salvador-Martín
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pharmacogenetics cardiology adverse events guidelines Medicine R
Acceso en línea:	https://doaj.org/article/ee9c57be612740ca8986a2041b14ae6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee9c57be612740ca8986a2041b14ae6c
record_format	dspace
spelling	oai:doaj.org-article:ee9c57be612740ca8986a2041b14ae6c2021-11-25T18:07:50ZPharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?10.3390/jpm111111802075-4426https://doaj.org/article/ee9c57be612740ca8986a2041b14ae6c2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1180https://doaj.org/toc/2075-4426Cardiovascular Diseases (CVs) are one of the main causes of mortality and disability around the world. Advances in drug treatment have greatly improved survival and quality of life in the past decades, but associated adverse events remain a relevant problem. Pharmacogenetics can help individualize cardiovascular treatment, reducing associated toxicities and improving outcomes. Several scientific societies and working groups periodically review available studies and provide consensus recommendations for those gene-drug pairs with a sufficient level of evidence. However, these recommendations are rarely mandatory, and the indications on how to adjust treatment can vary between different guidelines, which limits their clinical applicability. The aim of this review is to compile, compare and discuss available guidelines and recommendations by the main Pharmacogenetics Consortiums (Clinical Pharmacogenetics Implementation Consortium (CPIC); Dutch Pharmacogenetics Working Group (DPWG); the French Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx) and The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) regarding how to apply pharmacogenetic results to optimize pharmacotherapy in cardiology. Pharmacogenetic recommendations included in European or American drug labels, as well as those included in the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) and the American Heart Association (AHA) treatment guidelines are also discussed.Xandra García-GonzálezSara Salvador-MartínMDPI AGarticlepharmacogeneticscardiologyadverse eventsguidelinesMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1180, p 1180 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pharmacogenetics cardiology adverse events guidelines Medicine R
spellingShingle	pharmacogenetics cardiology adverse events guidelines Medicine R Xandra García-González Sara Salvador-Martín Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
description	Cardiovascular Diseases (CVs) are one of the main causes of mortality and disability around the world. Advances in drug treatment have greatly improved survival and quality of life in the past decades, but associated adverse events remain a relevant problem. Pharmacogenetics can help individualize cardiovascular treatment, reducing associated toxicities and improving outcomes. Several scientific societies and working groups periodically review available studies and provide consensus recommendations for those gene-drug pairs with a sufficient level of evidence. However, these recommendations are rarely mandatory, and the indications on how to adjust treatment can vary between different guidelines, which limits their clinical applicability. The aim of this review is to compile, compare and discuss available guidelines and recommendations by the main Pharmacogenetics Consortiums (Clinical Pharmacogenetics Implementation Consortium (CPIC); Dutch Pharmacogenetics Working Group (DPWG); the French Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx) and The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) regarding how to apply pharmacogenetic results to optimize pharmacotherapy in cardiology. Pharmacogenetic recommendations included in European or American drug labels, as well as those included in the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) and the American Heart Association (AHA) treatment guidelines are also discussed.
format	article
author	Xandra García-González Sara Salvador-Martín
author_facet	Xandra García-González Sara Salvador-Martín
author_sort	Xandra García-González
title	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
title_short	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
title_full	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
title_fullStr	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
title_full_unstemmed	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
title_sort	pharmacogenetics to avoid adverse reactions in cardiology: ready for implementation?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ee9c57be612740ca8986a2041b14ae6c
work_keys_str_mv	AT xandragarciagonzalez pharmacogeneticstoavoidadversereactionsincardiologyreadyforimplementation AT sarasalvadormartin pharmacogeneticstoavoidadversereactionsincardiologyreadyforimplementation
_version_	1718411594610769920

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Ejemplares similares